Skip to main content
CORDIS - Forschungsergebnisse der EU
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary
Inhalt archiviert am 2024-05-24

Quality of life following adherence therapy for people disabled by schizophrenia and their carers (QUATRO)

Ziel

Ant psychotic medication has well-established effectiveness in the treatment of people with schizophrenia. However, adherence to medication is a very common problem, and non-adherence increases the risk of relapse disability, and poor quality of life. The "Quality of Life following Adherence Therapy for People Disabled by Schizophrenia and their Carers" study is a randomised controlled trial and will investigate the effectiveness and cost effectiveness of adherence therapy designed to improve quality of life among schizophrenic patients and their carers. The study is expected to contribute to evidence-based practice in the care for people who suffer from schizophrenia, and their carers, across Europe.

Aufforderung zur Vorschlagseinreichung

Data not available

Koordinator

KING'S COLLEGE LONDON
EU-Beitrag
Keine Daten
Adresse
De Crespigny Park, Denmark Hill
SE5 8AF LONDON
Vereinigtes Königreich

Auf der Karte ansehen

Gesamtkosten
Keine Daten

Beteiligte (3)